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Abstract 
Leucine-rich repeat kinase 2(LRRK2) is the greatest known genetic contributor to Parkinson's 
disease (PD). LRRK2 encodes a 2527 amino-acid multi-domain protein. It has several regions 
predicted to be involved in protein-protein interactions, which include an ankyrin repeat 
domain, a leucine-rich repeat domain and a WD40 domain. It also has two catalytic domains 
including a kinase domain of the tyrosine kinase-like family and a GTPase domain of the Ras 
of complex proteins family (ROC). Tyrosine kinase and Ras family GTPases like kinases are 
often associated as elements of the same intracellular signalling pathway, that suggest a 
functional interaction between both of these catalytic functions within LRRK2. Roc GTPase 
domain represents hotspot for mutations it has three PD mutations at a single R1441 residue 
(i.e., R1441C, R1441G, and R1441H), two PD mutations at a single T1343 residue (i.e., 
T1343G and T1343V), N1437H, I1371V, K1347A, R1398H, and T1348N. Y1699C mutation 
is the only known disease-causing variant in COR domain. G2019S and I2020T, located in 
adjacent residues of the kinase activation loop, are known to cause familial PD. 
Mutation in LRRK2 causes impairment in GTPase activity and therefore alters kinase activity. 
Kinase activity of LRRK2 requires an intact of ROC and GTPase domain. The activity of 
LRRK2 kinase increases when GTP binds to the GTPase (ROC) domain. The increase in 
Kinase activity on GTP binding is the cause of PD as known for now. There is a number of 
mutations in the domains present in LRRK2 that is responsible for changes in GTPase activity 
and Kinase activity. Mutations in the catalytic ROC-COR and kinase domains of LRRK2 are 
considered as the most common causes of PD. Mutations located in the kinase domain 
influence only kinase activity whereas mutations in ROC domain may influence both GTP-
binding and kinase activity. The GTPase domain plays a role in regulating kinase activity, and 
in mediating the neurotoxic effects of LRRK2. Therefore, the GTPase domain and Kinase 
domain is studied as a therapeutic target for inhibiting the pathogenic effects of LRRK2 
mutations.  
LRRK2 Roc domain structure from UniProt: Q5S007 (LRRK2_HUMAN) and Homology 
modelling of Kinase domain are done in Swiss-Model to study the inhibition efficiency of GTP 
binding and Kinase activity.  
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1. INTRODUCTION:  
1.1 Neurodegenerative Diseases: 
Neurodegenerative disease is a term for a range of neuronal conditions. It is the progressive 
loss of function of neurons that leads to the death of neurons. Neurons are the building blocks 
of the nervous system which includes the brain and spinal cord. When neurons become 
damaged or die they cannot be replaced by the body as they don’t reproduce or replace 
themselves. Neurodegenerative diseases are incurable conditions that result in progressive 
degeneration and death of nerve cells, which causes ataxias or dementias. 
Example of neurodegenerative diseases are: 
 Alzheimer’s disease (AD)  
 Parkinson’s disease (PD)  
 Amyotrophic lateral sclerosis (ALS) 
 Prion disease 
 Huntington’s disease (HD) 
 Spinocerebellar ataxia (SCA) 
 Spinal muscular atrophy (SMA) 
 
In these study, I have taken Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) 
to construct the landscape of disease-causing mutation in neurodegenerative disease.  
ALS and PD are the second and third most common human adult-onset neurodegenerative 
diseases, respectively, after Alzheimer's disease (1).  
They are characterized by prominent age-related neurodegeneration in selectively vulnerable 
neural systems. Some forms of PD and ALS are inherited and some are sporadic and genes 
causing these diseases have been identified.  
Both ALS and PD are neurodegenerative diseases, and are characterized by the presence of 
intra-neuronal inclusions; however, different classes of neurons are affected and the primary 
protein in the inclusions differs between the diseases, and in some cases is different in distinct 
forms of the same disease. 
The major symptoms of both diseases arise from the degeneration of particular classes of the 
neuron: the dopaminergic neurons of the substantia nigra pars compacta in the case of PD and 
the spinal motor neurons in the case of ALS. 
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1.2 RNA Binding Proteins: 
RBPs are involved in all aspects of RNA processing, controlling the life cycle of RNAs from 
synthesis to degradation. Hallmark features of RBPs in neuron dysfunction include 
misregulation of RNA processing, mislocalization of RBPs to the cytoplasm, and abnormal 
aggregation of RBPs (2). Recent advances in neurodegenerative diseases point to novel 
mechanisms of protein aggregation that revolve around the unique biology of RNA binding 
proteins (3). RNA binding proteins normally are present in the nucleus (3). Under conditions 
of cell stress, these RNA binding proteins translocate to the cytoplasm where they form stress 
granules, which function in part to sequester specialized transcript and promote translation of 
protective proteins (3). Studies in humans show that pathological aggregates occurring in ALS, 
Alzheimer’s disease and other dementias co-localize with stress granules. Mutations in RNA 
binding proteins or prolonged periods of stress causes the formation of very stable, pathological 
stress granules (3). The consolidation of RNA binding proteins away from the nucleus and 
neuronal arbours into pathological stress granules might impair the normal physiological 
activities of these RNA binding proteins causing the neurodegeneration associated with these 
diseases.  
RBPs TDP-43 and FUS for ALS and SNCA and LRRK2 for PD are focused in this study. That 
is, how the mutations in these proteins cause the disease is studied. 
 
 
Figure from RNA-binding proteins implicated in neurodegenerative diseases; Mark R Cookson 
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Figure 1: RNA-binding proteins (RBPs) implicated in several neurological diseases. RBPs 
implicated in neurological diseases have a role in several steps of RNA processing, including 
transcription, alternative splicing, alternative polyadenylation, localization of transcripts, 
including sequestration into inclusions and stress granules, translation, RNA degradation, and 
turnover (4). The physiological functions of these RBPs often lend significant insights into the 
mechanisms of pathogenesis. 
 
 
RNA processing step, RNA binding proteins and the diseases:  
 
Transcription:  
                      Taf15, EWS, FUS (ALS/FTD) 
Alternative splicing:  
                              MBNL1/2, CuGBP (DM) 
                              TDP43, FUS, TAF15, hnRNPA1, hnRNPA2/B1, EWS (FTD/ALS) 
                              NOVA (POMA) 
                              RBFOX (Ataxia)  
Alternative polyadenylation:  
                                            NOVA (POMA) 
                                            MBNL1/2 (DM) 
                                            PABPN1 (OPMD)     
Localization transport and sequestration:  
                                          hnRNPA2/B1, TDP43, FUS, TAF15, EWS (ALS/FTD) 
                                          FMRP (FXS, FXTAS)  
                                          ATXN2 (SCA2, ALS)  
                                          SMN (SMA)   
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Degradation and turnover:  
CELF4, HuR/ELAVLI (PD)           
MATR3 (ALS) 
Translation: 
                  FMRP, DGCR8, DROSHA (FXS, FXTAS) 
                  hnRNPA2/B1, hnRNPA1 (ALS/FTD) 
                  PARK7 (PD) 
 
 
 
2. Scope of study:  
Since these RNA binding proteins are found to be aggregated and toxic in ALS and PD 
condition, it could be hypothesized to find some small molecules/phytochemical to inhibit the 
kinase activity and GTP binding. 
 
 
Objectives: 
1. To find the most common gene mutation of severely damaging protein in the 
pathogenesis.  
2. To find small molecules to inhibit the GTP binding and Kinase activity. 
3. Docking study with the protein and small molecule.  
 
3. Objective1:  
To find the most common gene mutation of severely damaging protein in the 
pathogenesis.  
The literature survey is done in order to find the epidemiology of ALS and PD, from the 
statistics of the gene which severely affects the population and which is prone to mutation 
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(hotspot for mutation) is found. The epidemiology statistics is done in order to narrow down 
the search to find the most common and severely affecting gene responsible for the disease 
pathogenesis. From several searches in database and literature survey.  
 
 
Table 1: Selected the gene targets for ALS and PD. 
 
Disease Genes selected 
PD LRRK2, SNCA 
ALS TDP-43, FUS 
 
 
 
3.1 Amyotrophic lateral sclerosis (ALS): 
 
Amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is a progressive 
neurodegenerative disease specifically affecting cortical and spinal motor neurons. It is 100% 
fatal. ALS usually strikes people between the ages of 40-70 and approximately 20,000 
Americans can have the disease at any given time (5).   
There are two different types of ALS, sporadic and familial.  
a) Sporadic ALS (sALS), accounts for 90 to 95 percent of all cases (5). The most common 
form of the disease in the U.S.  
b) Familial ALS (fALS) accounts for 5 to 10 percent of all cases in the U.S. In those 
families, there is 50% probability of each offspring to inherit the gene mutation and 
disease development. 
 
Cytoplasmic inclusions containing hyperphosphorylated and ubiquitinated TDP-43 are a 
pathological hallmark of ALS, and mutations in the gene encoding TDP-43 have been directly 
linked to the development of the disease (6). TDP-43 is a ubiquitous DNA/RNA-binding 
protein with a nuclear role in pre-mRNA splicing. 
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TDP-43 protein and FUS protein aggregates have been implicated in several cases of the 
disease, and the most common known cause of sporadic ALS is thought to be due to mutation 
in chromosome 9 (C9orf72) 
 
3.1.1 TDP-43 Is an ALS Disease Protein: 
TDP-43 was found in cytoplasmic inclusions in the diseased brain, which helped to understand 
the causes of ALS and methods to study its pathogenesis which was severely limited by an 
inability to identify ALS genes. After which many mutations in TDP43 were found in sALS 
and fALS cases, but not in control cases. 
TDP-43 has various roles in RNA metabolism, it is highly conserved, ubiquitously expressed 
protein (7). TDP-43 has two RNA Recognition Motifs (RRMs) and a C-terminal Glycine-rich 
domain. It is predominantly a nuclear protein, in ALS motor neurons which were found to 
mislocalize to the cytoplasm, with some affected neurons (8). TDP-43 was also found to be 
modified and to be misfolded in an aggregated state. Its modifications include ubiquitination, 
phosphorylation, and cleavage. The implications of these modifications as well as their origins 
and roles in ALS pathology is unclear. 
 
 
Figure 2: TDP-43 mutations in ALS: Mutations in TDP-43 identified in sALS and fALS 
patients. All are missense mutations. RRM1 and RRM2: RNA recognition motifs; NLS, 
nuclear localization signal; (NES), predicted nuclear export signal. 
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3.1.2 FUS (fused in sarcoma) Protein in ALS Disease:  
Like TDP-43, FUS is a ubiquitously expressed protein that is normally nuclear but is found in 
cytoplasmic inclusions in ALS brain (9). High levels of FUS (fused in sarcoma), either the 
normal or mutant forms, kill motor neurons, and certain mutations change the protein’s 
location, which might impair the normal functioning of neurons. 
Mutations in FUS account for ~35% of FALS in patients younger than 40 years old. Meta-
analyses of 154 ALS cases with FUS mutations (including FALS and SALS with de novo FUS 
mutations) show an average disease onset of 43.8±17.4 years. More than 60% of cases with 
FUS mutations show disease onset before 45 years of age, with many juvenile ALS cases 
presenting with disease onset in late teens and early 20's 
 
Mutation and proteinopathies in RNA binding protein FUS, which is closely related to TDP-
43, raises the intriguing possibility that perturbations to the RNA homeostasis and metabolism 
in neurons contribute to the pathogenesis of these diseases. They converge on the same 
mechanisms leading to neurodegeneration, unlike TDP-43 there is an evidence that FUS 
mutations target distinct mechanisms to cause early disease onset and aggressive progression 
of the disease. FUS mutations perturb the maintenance of dendrites through fundamental 
processes in RNA splicing, RNA transport and DNA damage response/repair (10).  
FUS contains an N-terminal QGSY-rich domain, followed by a Glycine-rich domain, an RRM, 
and two RGG-rich domains. Like TDP-43, FUS has roles in a number of different RNA-
processing activities, including splicing and mRNA export to the cytoplasm (9). About 50 
ALS-linked FUS mutations have been identified. 
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Figure 3: Genomic organization of the human FUS Gene, FUS mutations identified in ALS, 
and functional domains in FUS proteins.  
 
3.2 Parkinson's disease  
Parkinson's disease is the second most common neurodegenerative disease and manifests as 
bradykinesia, rigidity, resting tremor and posture instability. Parkinson's disease is a 
degenerative disorder of the central nervous system. It results from the death of dopamine-
generating cells in the substantia nigra, a region of the midbrain; the cause of cell-death is 
unknown. PD is characterized by the core motor symptoms collectively called parkinsonisms, 
including resting tremor, bradykinesia, muscle rigidity, postural instability and gait 
impairment, and it is also accompanied by a range of non-motor symptoms, which include 
constipation, urinary symptoms, sleep disorder, and dementia. The mechanism by which the 
brain cells in Parkinson's are lost may consist of an abnormal accumulation of the 
protein alpha-synuclein bound to ubiquitin in the damaged cells (11). The 
protein accumulation forms cytoplasmic inclusions called Lewy bodies.  
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Figure from: Blausen Gallery 2014/wikiversity journal of medicine, 
doi:10.15347/wjm/2014.010. 
Figure 4: A brain without and with Parkinson's Disease compared in Substantia Nigra 
 
 
 
Figure from: anti- agingfirewalls.com 
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Figure 5: Decreased in dopamine level produced by the neurons affected by Parkinson’s disease 
as a result less dopamine is available to bind to the dopamine receptor on the post-synaptic 
membrane.  
 
An estimated seven million to 10 million people worldwide have Parkinson’s disease. 10 
percent of family history. The prevalence of the disease ranges from 41 people per 100,000 in 
the fourth decade of life to more than 1,900 people per 100,000 among those 80 and older. An 
estimated 4 percent of people with Parkinson’s are diagnosed before the age of 50. 
The crude prevalence rate of PD has been reported to range from 15 per 100,000 to 12,500 per 
100,000, and the incidence of PD from 15 per 100,000 to 328 per 100,000, with the disease 
being less common in Asian countries.  
Men are 1^1/2 times more likely to have Parkinson’s than women. 
 
Parkinson’s statistics in selected countries 
United States 
About 1million Americans are thought to have Parkinson’s. 
Every year, about 60,000 Americans are diagnosed with Parkinson’s.  
Canada 
There are over 100,000 Canadians living with Parkinson’s today and approximately 6,600 new 
cases of PD are diagnosed each year in Canada. 
About 56 percent of patients receive formal or informal assistance due to their condition. Of 
those who receive it, 84 percent rely on family, friends or neighbours, while 56 percent obtain 
other assistance. 
United Kingdom 
The prevalence of Parkinson’s in the United Kingdom is one in 500 people, with about a total 
of about 127,000 people having the disease. Reports show that every hour, someone is 
diagnosed with Parkinson’s in Britain. Most are 50 or older. 
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The main known risk factor is age. Genes implicated in the development of PD include SNCA, 
LRRK2, GBA, PRNK, PINK1, PARK7, VPS35, EIF4G1, DNAJC13 AND CHCHD2.  
Mutations in some genes, including SNCA, LRRK2 and GBA, have been found to be risk 
factors for "sporadic" (non-familial) PD. LRRK2 is one of the 20,000 genes which are passed 
from parents to children. Mutations in the gene LRRK2 are the most common known cause of 
familial and sporadic PD, accounting for approx. 5% of individuals with a family history of the 
disease and 3% of sporadic cases. 
 
3.2.1 α-Synuclein and LRRK2: 
α-synuclein expressed highly in the brain, it is a 14 kDa neuron protein. Normally, α-synuclein 
is typically associated with synaptic vesicles at axon terminals. The physiological role of α-
synuclein is unclear (12). The increase in striatal alpha-synuclein levels induces increased 
Lrrk2 mRNA levels which suggested that Lrrk2 and alpha-synuclein mRNA levels are possibly 
co-regulated (12). G2019S mutation in Lrrk2 has a significantly greater capacity than wild-
type Lrrk2 to phosphorylate alpha-synuclein. Loss of LRRK2, on the other hand, seems to 
cause both accumulation and aggregation of SNCA. Co-immunoprecipitation showed that 
endogenous LRRK2 and α-synuclein have interaction in cells, mouse and human brain tissue. 
 
 
3.2.2 SNCA; α-Synuclein: 
α-Synuclein is a neuronal protein that is linked genetically and neuropathologically to 
Parkinson's disease (PD). α-Synuclein contributes to PD pathogenesis in a number of ways, but 
it is generally thought that its aberrant soluble oligomeric conformations, termed protofibrils, 
are the toxic species that mediate disruption of cellular homeostasis and neuronal death, 
through effects on various intracellular targets, including synaptic function (12). 
α-Synuclein is a member of the synuclein family of proteins, which also include β- and γ-
synuclein. The only difference of α-synuclein from the other members structurally is the NAC 
region. All three are neuronal proteins that localize preferentially to presynaptic 
terminals.  Point mutations in β-synuclein in rare cases causes DLB and neurodegeneration. 
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But wild-type β-synuclein is protective in various settings against α-synuclein-mediated 
neurodegeneration 
The SNCA gene encodes for a 140 amino acid protein, which in aqueous solutions does not 
have a defined structure, hence the term “natively unfolded protein.” α-Synuclein does form α-
helical structures on binding to negatively charged lipids, such as phospholipids present on 
cellular membranes, and β-sheet-rich structures on prolonged periods of incubation. The 
protein is composed of three distinct regions: 
(1) an amino terminus (residues 1–60), containing apolipoprotein lipid-binding motifs, which 
are predicted to form amphiphilic helices conferring the propensity to form α-helical structures 
on membrane binding,  
(2) a central hydrophobic region (61–95), so-called NAC (non-Aβ component), which confers 
the β-sheet potential, and  
(3) a carboxyl terminus that is highly negatively charged, and is prone to be unstructured. There 
are at least two shorter alternatively spliced variants of the SNCA gene transcript, but their 
physiological and pathological roles have not been well characterized. 
 
 
Figure 6: Scheme representing the structure of human ASYN with the three distinct domains 
(N-terminal, NAC and C-terminal).  
 
3.2.3 Effect of mutations on ASYN oligomerization and aggregation:  
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From Epifluorescence microscopy known that, all the ASYN variants formed oligomers in 
HEK cells. 
The aggregation paradigm shows that, the seven ASYN mutations (A30P, E46K, A53T, E35K, 
E57K, TP and Y125F) had the most pronounced effects for subsequent analysis. ASYN 
mutants could be examined using different assays, including toxicity measurements, 
biochemical analysis of ASYN, ASYN secretion, degradation pathways, in order to obtain 
detailed information on the cellular effects of specific types of ASYN accumulations. 
 
 
3.2.4 LRRK2 (Leucine-rich repeat kinase 2): 
LRRK2 is a member of the leucine-rich repeat kinase family. Variants of this gene are 
associated with an increased risk of Parkinson’s disease. A large number of 
novel LRRK2 mutations have been described as putative causes of PD.  
 
 
 
Figure 7: Structure of the leucine‐rich repeat kinase 2 protein and functional domains and PD-
linked point mutations 
 
 
3.2.5 Normal function of LRRK2: 
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The LRRK2 gene provides instructions for making a protein called dardarin. The LRRK2 gene 
is active in the brain and other tissues throughout the body. 
Dardarin has an enzyme function known as kinase activity. Proteins with kinase activity assist 
in the transfer of a phosphate group (a cluster of oxygen and phosphorus atoms) from the energy 
molecule ATP to amino acids in certain proteins. Dardarin also has a second enzyme function 
referred to as a GTPase activity. This activity is associated with a region of the protein called 
the ROC domain. The ROC domain may help control the overall shape of the dardarin protein. 
 
3.2.6 Mutation in LRRK2 causes PD: 
 
Mutations in Leucine-rich repeat kinase-2 (LRRK2) cause a genetic form of PD and have 
implications in sporadic PD. LRRK2 is a cytoplasmic protein and contains both GTPase and 
kinase domains. Mutations in the catalytic Roc-COR and kinase domains of LRRK2 are 
considered common causes of familial PD. LRRK2 mutations causes PD with age-related 
penetrance and clinical features identical to late-onset sporadic PD. There is an increase in 
LRRK2 kinase activity for kinase domain and a decrease in GTPase activity for Roc-COR 
mutations.  
Mutations in the LRRK2 gene and especially the common mutation G2019S may account for 
4–8% of familial and 1–3% of sporadic cases of Parkinson's disease, including those of early 
and late onset. The LRRK2 gene is situated on chromosome 12p11.2–q13.1. Dardarin contains 
several functional domains, including a leucine‐rich repeat domain, WD40, renin-angiotensin 
system/guanosine triphosphatases and kinase domains. The presence of the leucine‐rich repeat 
and WD40 domains suggests a role in protein-protein interaction. Frequencies of G2019S 
LRRK2 mutations vary significantly across different ethnic groups: 
Caucasian: 5% of familial PD cases and approximately 2% of apparently sporadic PD cases. 
Ashkenazi Jewish: 40% of familial and 13% of sporadic  
North African Berber Arabs: 39% of familial cases and 40% of sporadic cases.  
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Asian population shows that 2 protein-coding variants, G2385R and R1628P, increase the risk 
for PD approximately by 2-fold; these mutations are present at a frequency of approximately 
6% in cases. 
 
 
 
 
4. Objective 2: 
To find small molecules to inhibit GTP binding and kinase activity. 
 
To find the small molecule, several chemical databases like PubChem, drug bank etc. along 
with the literature study is done and the suitable physio chemical properties of the 
phytochemicals are studied. The Roc-COR domain LRRK2 gene responsible for PD is taken 
to study the GTP binding and kinase activity. 
For inhibiting kinase activity several kinase inhibitors are studied of which I have selected 
Nilotinib and Sunitinib based on the idea of their interactions and pharmacology. Also as it has 
been studied to some extent for other Neurodegenerative diseases such as Alzheimer’s. The 
GTP binding inhibitor compound 68 and FX2149 which can reduce LRRK2 GTP binding 
activity and can reduce LRRK2 kinase activity and protect against mutant LRRK2 toxicity. 
The structure of small molecules is drawn in 2D sketcher from the Schrodinger software which 
is then converted to 3D for the docking studies. 
 
4.1: 2D structure of small molecules: 
i. Nilotinib: Kinase inhibitor 
Molecular Formula: C28H22F3N7O 
Molecular weight: 592.527 
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Figure 8: Structure of Nilotinib. 
ii. Sunitinib: Kinase inhibitor 
Molecular Formula: C22H27FN4O2 
Molecular weight: 398.482 
Structure: 
 
 
Figure 9: Structure of Sunitinib.  
iii. Compound 68: GTP binding inhibitor 
Molecular Formula: C16H19N2O4S 
Molecular weight:334 
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Figure 10: Structure of compound 68. 
iv. FX2149: GTP binding inhibitor 
 
Molecular Formula: C15H17N3O3S 
Molecular weight:319 
 
 
 
 
Figure 11: Structure of FX2149. 
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5. Objective 3: 
Docking study with the protein and small molecule.  
The docking and scoring are done with help of Schrodinger software. The Protein (LRRK2) 
structure is taken from UniProt. Which covers the Roc domain of LRRK2 that is residues from 
amino acids 1333–1516. PD-linked mutations within the GTPase domain alter either GTP 
binding or GTPase activity. GTP binding by the K1347A mutation alters LRRK2 kinase 
activity. As the structure of COR region of GTPase domain is not available Homology 
modelling is done to build the structure in Swiss Model. 
 
5.1 Introduction to software: 
The following gives a brief introduction of the software that is used to derive the results of 
Docking and Scoring.  
 
Schrodinger:  
A software that is considered as the scientific leader in developing the state-of-the-art 
chemical simulation for use in pharmaceutical, biotechnology, and materials science 
research.  
 
Maestro:  
Maestro is the portal to all of Schrodinger's computational technology. The powerful, 
unified portal to modelling small-molecules, biologics, and materials with Schrodinger 
technology. Far more than just a user interface, Maestro also helps researchers organize 
and analyze data. 
Specific buttons, menus, and other controls that can be found in the Maestro user interface. The 
image below shows the maestro portal. The interface consists of three main regions: the 
selection toolbar, with its selection tools and primary actions; the workspace navigator with its 
two panes for managing and reviewing content. 
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Figure 12: Layout of Maestro. 
 
 
5.2 Docking:  
Also referred to as small molecular docking is a method that predicts the best orientation of 
one molecule to the other when bound to each other to form a stable complex. Molecular 
docking is one of the most frequently used methods in structure-based drug design, due to its 
ability to predict the binding-conformation of small molecule ligands to the appropriate 
target binding site. Molecular docking is a study of how two or more molecular structures, for 
instance, drug and catalyst or macromolecule receptor, match along to be a perfect fit. Binding 
orientation of small-molecule drug candidates to their macromolecular targets predicts the 
affinity and activity of a given small molecule.  
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Task Tool Building and 
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5.3 Methodology: 
5.3.1 Protein Preparation:  
The typical protein structure file taken from the PDB is not suitable for immediate use in 
molecular modelling calculation. They usually consist of heavy atoms and may include a co-
crystallized ligand, water molecules, metal ion and cofactors. Some structures are multimeric 
and need to be reduced to a single unit and because of the limited resolution of X-ray 
experiments, it can be difficult to distinguish between the carboxyl oxygen and secondary 
amine nitrogen of amides in the crystal structure. So, the placement of these groups must be 
checked. PDB structure may also present with missing atoms and connectivity information 
which must be assigned along with bond orders and charges. Therefore, protein preparation is 
a must before performing molecular modelling. 
To do the protein preparation, in the maestro portal click the task toolbar and take protein 
preparation wizard. The protein preparation wizard consists of a series of tools to prepare 
proteins in a form that is suitable for modelling and calculations. 
There are three tabs in the protein preparation wizard. These wizards consist of all the tools for 
stages of the protein preparation. 
1.Import and process tab: Properties structure can be imported and a basic task for fixing the 
structure can be performed. 
2.Review and modify tab: Unwanted waters and chains can be deleted and fix or delete het 
groups. 
3.Refined tab: It can be used to optimize the orientation of H-bonded groups and minimize the 
structure. 
All these 3-stages should be performed for an unprocessed protein, such as the one from the 
PDB. When the protein is ready to use, the grid points are set using the Glide Grid Generation. 
 
5.3.2 Ligand Preparation:  
To prepare the ligands to use in computational studies such as Schrodinger modeling 
application for docking. Go to the task and click on LigPrep. The LigPrep panel opens which 
shows several options used for preparing the ligand. The ligand structure imported in the 
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workspace is used. So, the option “use structure from project table” is used in the procedure. 
The other criteria such as ionization state, choosing stereoisomers, desalt, choosing the output 
format are selected according to the requirement. After completion of which the name of the 
job is renamed as preferred and the job is run. It takes 10-15 minutes of running time to 
complete the job. The structure of some ligands appears multiple times represented by different 
ionization or tautomeric states. In the project table click the property tree and show only the 
Epik results. The one which has the lowest Epik penalty among the structures represents the 
more energetically favorable state than the one with more penalty value. Therefore, the 
structures are fully prepared to be used in further computational studies within the Schrodinger 
suite. 
 
 
5.3.3 Protein–ligand docking:  
It is the most commonly used docking technique. It predicts the position of a ligand when it is 
bound to the protein. The ligand might act as an inhibitor or a promoter. In the maestro portal 
go to the task then click to Glide Docking, when the ligand docking window is open, in the 
option receptor grid, browse the protein whose grid point is set in the Receptor Grid Generation. 
Next, in use ligand from option select project table selected entries. Keep the scaling factor 
0.08. Rename the job name and run the job. The running time of the job is about 10-20 minutes. 
Once the job is done the docked product will appear in the workspace, which is further used 
for a binding affinity study using Prime MM-GBSA.   
 
 5.3.4 MM-GBSA:  
Molecular Mechanics‐Generalized Born Surface Area (MM‐GBSA) calculations. It is a 
method to calculate relative binding free energy for molecules by combining molecular 
mechanics calculations and continuum (implicit) solvation models. The absolute values 
calculated are not necessarily in agreement with experimental binding affinities. The ranking 
of the ligands based on the calculated binding energies (MMGBSA DG Bind) can be expected 
to agree reasonably well with ranking based on experimental binding affinity, particularly in 
the case of congeneric series.  
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The job running time of MM-GBSA takes about 9-10 hours. A more negative value indicates 
stronger binding as the MM-GBSA binding energies are approximate free energies of binding. 
 
 
6. Results: 
  6.1 Roc domain study: 
The Roc domain of the LRRK2 protein is studied and one of the mutations (K1347A), that is 
playing a role in causing the PD is considered in this study. K1347A is said to impair the 
GDP/GTP binding. The most common PD-linked mutation, G2019S, has abnormally elevated 
kinase activity. The GTP binding by the K1347A mutation increases LRRK2 kinase activity, 
which is the reason that causes PD. 
 
 
(A)                                                                        (B) 
Figure 13: ROC domain of LRRK2 protein. (A) Wild Type Lys1437 residue and (B) 
Mutation of LYS to ALA1347.       
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6.2 Docking of small molecule and Binding affinity analysis: 
The kinase inhibitor Nilotinib and the GTP binding inhibitor FX2149 and Compound 68 taken 
as a small molecule are prepared in the Maestro portal’s LigPrep. Likewise, the Roc domain of 
the LRRK2 protein is prepared by the Protein preparation wizard. Through these, the small 
molecules’ and the protein’s unwanted particles are removed and are made compatible for 
Docking. The already present ligand of the protein of interest is been removed to dock with the 
selected inhibitors. The Grid point where the molecule is to be docked is set by using the 
Receptor Grid generation. The results of which are saved as glid_grid_4 for Wild Type and 
glid_grid_7 for Mutant protein. Finally, these two completely prepared proteins are further 
used in docking process. The docking is done by incorporating the small molecule in the place 
of the removed ligand that was already present in the raw protein and whose grid has been set 
for the area of interest in the protein. Thereafter, the binding affinity of the small molecules to 
the protein is calculated by the method MMGBSA. Figure 14, figure 18, and figure 22 shows 
the ΔG value of wild type protein with the Nilotinib, FX2149 and Compound 68 complex 
respectively. Similarly, figure 16, figure 20, figure 24 shows the ΔG value of mutant protein 
with the Nilotinib, FX2149 and Compound 68 complex respectively. 
 
Figure 14: ΔG value of WT Roc domain and Kinase inhibitor Nilotinib complex calculated 
by MMGBSA method. 
From the MMGBSA study, the two highest negative value is selected as it indicates stronger 
binding since the MM-GBSA binding energies are approximate free energies of binding. The 
orientation with the highest negative value in the binding of these small molecules is considered 
to be the most ideal. Then the two structures are studied further, and their interaction between 
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the wild-type domain, and small molecules as well as how they differ with the mutant domain, 
and small molecule interaction is compared. Figure 15, Figure 19, Figure 23 shows the 
interaction between wild-type Roc domain of LRRK2 protein with the kinase inhibitor 
Nilotinib, and GTP binding inhibitors FX2149, and Compound 68 respectively. The interaction 
between mutant Roc domain of LRRK2 protein with the Kinase inhibitor Nilotinib, and GTP 
binding inhibitors FX2149 and Compound 68 are shown in the Figure 17, Figure 21 and Figure 
23 respectively. The binding affinity is good enough to say that the small molecule inhibitors 
would work as a good inhibitor and could be used to inhibit the GTP binding to stop the kinase 
activity that is said to causes the PD.  
 
   
 
Figure 15: Interaction between wild type Roc domain of LRRK2 protein with the Kinase 
inhibitor Nilotinib. 
                                  
 
 
 
 
 
(A) (B) 
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Figure 16: ΔG value of Mutant Roc domain and Kinase inhibitor Nilotinib complex 
calculated by MMGBSA method. 
 
 
Figure 17: Interaction between mutant Roc domain of LRRK2 protein with the Kinase inhibitor 
Nilotinib. 
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Figure 18: ΔG value of wild type Roc domain and GTP binding inhibitor FX2149 complex 
calculated by MMGBSA method. 
 
 
 
Figure 19: Interaction between Wild Type Roc domain of LRRK2 protein with the GTP 
binding inhibitor FX2149. 
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Figure 20: ΔG value of Mutant Roc domain of LRRK2 protein and GTP binding inhibitor 
FX2149 complex calculated by MMGBSA method. 
 
 
Figure 21: Interaction between Mutant Roc domain of LRRK2 protein with the GTP binding 
inhibitor FX2149. 
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Figure 22: ΔG value of wild type Roc domain and GTP binding inhibitor compound 68 
complex calculated by MMGBSA method. 
 
 
 
Figure 23: Interaction between WT Roc domain of LRRK2 protein with the GTP binding 
inhibitor compound 68. 
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Figure 24: ΔG value of Mutant Roc domain and GTP binding inhibitor compound 68 
complex calculated by MMGBSA method. 
 
 
Figure 25: Interaction between Mutant Roc domain of LRRK2 protein with the GTP binding 
inhibitor compound 68. 
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Figure 26: ΔG value of WT Roc domain and GDP complex calculated by MMGBSA method. 
 
 
Figure 27: Interaction between WT Roc domain of LRRK2 protein with the GDP. 
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Figure 28: ΔG value of Mutant Roc domain and GDP complex calculated by MMGBSA 
method. 
 
 
 
Figure 29: Interaction between Mutant Roc domain of LRRK2 protein with the GDP. 
 
 
 
7. Conclusion: 
LRRK2 is the main causative protein in PD and an attractive target for therapeutic 
development. Though the LRRK2-related mechanisms leading to neurotoxicity remain 
incompletely understood, recent studies have brought to an idea that the kinase activity of 
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LRRK2 is a key therapeutic target since the most common G2019S mutation increases kinase 
activity and induces neuronal toxicity. LRRK2 contains an evolutionarily conserved Roc-COR 
tandem domain, and many familial mutations are clustered within the Roc and COR domains 
and impair GTPase activity. Therefore, GTPase activity is important for LRRK2 function, for 
regulating kinase activity, and for the development of PD. The mutation K1347A impairs GTP 
binding activity and is responsible to increase the kinase activity of G2019S. If the GTP binding 
could be prohibited by GTP binding inhibitor there might not be the elevation of kinase activity. 
Potential therapeutic strategies for targeting the Roc-COR tandem domain might include 
inhibition of GTP binding and kinase inhibition. So, taking these into an account a small 
molecule inhibitors are studied and the docking study is done.  
The molecular docking approach can be used to model the interaction between small molecule 
and a protein at the atomic level, which allows to characterize the behaviour of small molecules 
in the binding site of target proteins as well as to explain fundamental biochemical processes. 
The docking process involves two basic steps: prediction of the ligand conformation as well as 
its position and orientation within these sites and assessment of the binding affinity. These two 
steps are related to sampling methods and scoring schemes, respectively. Knowing the location 
of the binding site before docking processes significantly increase the docking efficiency. 
Computationally the inhibitors taken for this study is found to be compatible. Although, the 
validation of each of these strategies is now required in disease-relevant models and may rely 
upon the future development of small-molecule compounds.  
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